![Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap](https://www.aidsmap.com/sites/default/files/styles/aidsmap_medium_crop/public/2014-07/reduced-treatment-delays-for-people-with-drug-resistant-tb-and-hiv-co-infection-through-decentralised-care-and-rapid-xpert-mtb-rif-test.jpg?itok=a3BvZKPH)
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap
![Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study - eClinicalMedicine Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study - eClinicalMedicine](https://www.thelancet.com/cms/attachment/874b98dc-08c4-4b37-9933-d1ec91a73277/gr1_lrg.jpg)
Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study - eClinicalMedicine
![Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/635ff583-3864-4e80-9257-e0e627797da0/gr1_lrg.jpg)
Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases
![Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances](https://www.science.org/cms/10.1126/sciadv.aba4901/asset/00383882-f2bd-45d4-afc8-799ed66567e0/assets/graphic/aba4901-f1.jpeg)
Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances
![Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019 | SpringerLink Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40121-020-00368-5/MediaObjects/40121_2020_368_Fig1_HTML.png)
Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019 | SpringerLink
![Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial | BMC Infectious Diseases | Full Text Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial | BMC Infectious Diseases | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12879-019-4697-5/MediaObjects/12879_2019_4697_Fig1_HTML.png)
Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial | BMC Infectious Diseases | Full Text
![Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study - International Journal of Infectious Diseases Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study - International Journal of Infectious Diseases](https://www.ijidonline.com/cms/asset/7a927e94-eb43-4981-8626-24bac7a26b1b/gr1.jpg)
Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study - International Journal of Infectious Diseases
![A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis](https://redetb.org.br/wp-content/uploads/2022/08/55488877999-750x360.png)
A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis
![Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study | BMC Infectious Diseases | Full Text Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study | BMC Infectious Diseases | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12879-020-05073-9/MediaObjects/12879_2020_5073_Fig1_HTML.png)
Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study | BMC Infectious Diseases | Full Text
![Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart Drug Resistance | Newsroom | Weill Cornell Medicine Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart Drug Resistance | Newsroom | Weill Cornell Medicine](https://news.weill.cornell.edu/sites/default/files/styles/news_story_featured_image/public/story_featured_images/mtb_in_macs_brighter_002.png?itok=_E1sKM3X&c=6c6241230839d973c839aaa112647734)
Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart Drug Resistance | Newsroom | Weill Cornell Medicine
![Figure 3 - Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC Figure 3 - Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC](https://wwwnc.cdc.gov/eid/images/15-1227-F3.jpg)